Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2β- carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 147-152

  Chalon, Sylvie ^a,b   Hall, Hakan ^c   Saba, Wadad ^d   Garreau, Lucette ^a,b   Dollé, Frédéric ^d   Halldin, Christer ^c   Emond, Patrick ^a,b   Bottlaender, Michel ^d   Deloye, Jean Bernard ^e   Helfenbein, Julie ^f   Madelmont, Jean Claude ^a   Bodard, Sylvie ^a,b   Mincheva, Zoïa ^a,b   Besnard, Jean Claude ^a,b   Guilloteau, Denis ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DIF   (France)

^e Academisch Centrum Kinder en Jeugdpsychiatrie Curium   (France)

^f Orphachem   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLAMINE DERIVATIVE; CITALOPRAM; DOPAMINE TRANSPORTER; FLUORIDE; LBT 999; N (4 FLUOROBUT 2 ENYL) 2 BETA CARBOMETHOXY 3 BETA (4' TOYL)NORTROPANE; N,N DIMETHYL 2 (2 AMINO 4 METHYL PHENYL THIO)BENZYLAMINE; NISOXETINE; PAROXETINE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; IN VITRO STUDY; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RADIOACTIVITY; RAT; THALAMUS;

ANIMALS; AUTORADIOGRAPHY; BICYCLO COMPOUNDS; BINDING, COMPETITIVE; BRAIN; CELL MEMBRANE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ESTERS; HUMANS; LIGANDS; PAPIO; RATS; TISSUE DISTRIBUTION;

EID: 33645119477     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.096792     Document Type: Article

References (39)

1. 123I]FPCIT SPECT. J Nucl Med 40:753-761.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JC, and Guilloteau D (1999) Pharmacological characterization of (E)-N-(3-iodoprop-2- enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291:648-654.
4. 18F]N-(3-fluoropropyl)-2-β-carbomethoxy-3-β-(4-bromophenyl) nortropane and the regional brain uptake in non human primate using PET. Nucl Med Biol 31:125-131.
5. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with Positron Emission Tomography. Nucl Med Biol 23:999-1004.
6. 18F]FECNT. J Nucl Med 44:855-861.
7. 18F]FECNT. J Nucl Med 42:376-381.
8. 11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET. J Label Compd Radiopharm 43:997-1004.
9. 11C]deprenyl, a selective radioligand for the quantification of MAO-B activity using PET. J Label Compd Radiopharm 45:803-811.
10. 11C]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET. Bioorg Med Chem 14:1115-1125.
11. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, Frangin Y, Mauclaire L, Besnard J-C, and Guilloteau D (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′- iodophenyl) nortropane and N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β- (3′,4′-disubstituted phenyl)nortropane: new high-affinity and selective compounds for the dopamine transporter. J Med Chem 40:1366-1372.
12. Emond P, Vercouillie J, Innis R, Chalon S, Mavel S, Frangin Y, Halldin C, Besnard J-C, and Guilloteau D (2002) Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation. J Med Chem 45:1253-1258.
13. Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, et al. (1998) Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 29:128-141.
14. Goodman MM, Keil R, Shoup T, Eshima D, Eshima L, Kilts CD, Votaw J, Camp VM, Votaw D, Smith E, et al. (1997) Fluorine-18 labeled 2β-carbomethoxy- 3β-(4-chlorophenyl)-8-(3-fluoropropyl)nortropane (FPCT): a PET radiotracer for imaging dopamine transporters. J Nucl Med 38:119-126.
15. 18F-Labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporter. Nucl Med Biol 27:1-12.
16. Guilloteau D, Emond P, Baulieu J-L, Garreau L, Frangin Y, Pourcelot L, Mauclaire L, Besnard J-C, and Chalon S (1998) Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β- carbomethoxy-3β-(4′-methylphenyl) nortropane (PE2I). Nucl Med Biol 25:331-337.
17. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naïve Parkinson's disease: implications for the symptomatic threshold. Neurology 48: 1578-1583.
18. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. Synapse 23:321-327.
19. Hall H, Halldin C, Farde L, and Sedvall G (1998) Whole hemisphere autoradiography of the postmortem human brain. Nucl Med Biol 25:715-719.
20. 125I]PE2I. NeuroImage 9:108-116.
21. Hall H, Hurd Y, Pauli S, Halldin C, and Sedvall G (2001) Human brain imaging post-mortem - whole hemisphere technologies. Int Rev Psychiatry Res 13:12-17.
22. 11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30:1220-1230.
23. Ilgin N, Zubieta J, Reich SG, Dannals RF, Ravert HT, and Frost JJ (1999) PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology 52:1221-1226.
24. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, et al. (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90:11965-11969.
25. Jucaite A, Fernell E, Halldin C, Forssberg H, and Farde L (2005) Reduced midbrain dopamine transporter binding in male adolescent with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57:229-238.
26. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, Margouleff D, Neumeyer JL, and Eidelberg D (1998) Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 39:1521-1530.
27. 18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: characterization in human subjects. Synapse 28:244-250.
28. 11C]methyl triflate. J Label Compd Radiopharm 42:1183-1193.
29. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, and Frackowiak RS (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47:1290-1298.
30. 18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 45:125-133.
31. Meltzer PC, Liang AY, Brownell A-L, Elmaleh DR, and Madras BK (1993) Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites and positron emission tomography imaging. J Med Chem 36:855-862.
32. 99mTc] TRODAT-1 to dopamine transporters in patients with Parkinson's disease and healthy volunteers. J Nucl Med 41:584-589.
33. Neumeyer JL, Tamahgnan G, Wang S, Gao Y, Milius RA, Kula NS, and Baldessarini RJ (1996) N-Substituted analogs of 2β-carbomethoxy-3β- (4′-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 39:543-548.
34. 18F]CFT. Ann Neurol 47:804-808.
35. 123I]PE2I binding to dopamine transporters with SPET. Eur J Nucl Med 29:623-631.
36. 11C]FLB 457 by use of the GE medical systems PETtrace MeI MicroLab. J Label Compd Radiopharm 43:331-338.
37. Sanders JD, Happe HK, Bylund DB, and Murrin LC (2005) Development of the norepinephrine transporter in the rat CNS. Neuroscience 130:107-117.
38. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, and Tatsch K (2000) Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 57:205-208.
39. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, and Innis RB (1998) Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 39:1500-1508.